HORSHAM, Pa.--(BUSINESS WIRE)--PhotoMedex, Inc. (NasdaqGS and TASE:PHMD) announces the sale of its worldwide XTRAC® and VTRAC® psoriasis and vitiligo treatment businesses to MELA Sciences, Inc. (Nasdaq:MELA) for $42.5 million in cash. In addition, the company announces it has paid off in full all outstanding debt, which totaled $40.1 million as of June 22, 2015. “PhotoMedex is now able to focus solely on our core consumer and skincare businesses, including the no!no!™, Kyrobak® and Neova® brand
| < Prev | Next > |
|---|
